Gensight Biologics S.a annual book value per share
2020
2021
2022
2023
2024
2025
Gensight Biologics S.a Book Value Per Share Growth & History (SIGHT)
Gensight Biologics S.a's book value per share was -€0.11 for fiscal 2025.
View full Gensight Biologics S.a company overviewGensight Biologics S.a annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | -€0.11 | €0.10 | — |
| 2024 | 2024-12-31 | -€0.22 | €0.25 | — |
| 2023 | 2023-12-31 | -€0.47 | -€0.14 | — |
| 2022 | 2022-12-31 | -€0.33 | -€0.68 | — |
| 2021 | 2021-12-31 | €0.35 | €0.06 | +20.14% |
| 2020 | 2020-12-31 | €0.29 | — | — |
Gensight Biologics S.a quarterly book value per share
Q4.24
Q4.25
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | -€0.11 | €0.11 | — |
| Q4 2024 | 2024-12-31 | -€0.22 | — | — |
Gensight Biologics S.a book value per share trends
Over the last five fiscal years, Gensight Biologics S.a's book value per share decreased from €0.29 to -€0.11, a change of -€0.40. The latest reported quarter, Q4 2025, shows -€0.11.
About the metric
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
Calculation and source
How book value per share is calculated
TickerStat calculates book value per share as reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gensight Biologics S.a source filings ↗Community posts
GenSight advances LUMEVOQ manufacturing transfer to Catalent
GenSight ($SIGHT) said an engineering batch of GS010/LUMEVOQ at Catalent was produced as planned, with viral genome concentration meeting target specifications. Preparations have begun for a GMP-standard batch to supply special-access progr ...